Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 2 | 9 |
| 1.1 List of Tables | 5 | 5 |
| 1.2 List of Figures | 10 | 1 |
| 2 Introduction | 11 | 1 |
| 2.1 Bioabsorbable Stents (BAS) Overview | 11 | 1 |
| 3 Products under Development | 12 | 5 |
| 3.1 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development | 12 | 1 |
| 3.2 Bioabsorbable Stents (BAS) - Pipeline Products by Territory | 13 | 1 |
| 3.3 Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path | 14 | 1 |
| 3.4 Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date | 15 | 1 |
| 3.5 Bioabsorbable Stents (BAS) - Ongoing Clinical Trials | 16 | 1 |
| 4 Bioabsorbable Stents (BAS) - Pipeline Products under Development by Companies | 17 | 4 |
| 4.1 Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development | 17 | 2 |
| 4.2 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development | 19 | 2 |
| 5 Bioabsorbable Stents (BAS) Companies and Product Overview | 21 | 84 |
| 5.1 Abbott Vascular Inc. Company Overview | 21 | 1 |
| 5.1.1 Abbott Vascular Inc. Pipeline Products &Ongoing Clinical Trials Overview | 21 | 24 |
| 5.2 Amaranth Medical, Inc. Company Overview | 45 | 1 |
| 5.2.1 Amaranth Medical, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 45 | 9 |
| 5.3 Arterius Ltd Company Overview | 54 | 1 |
| 5.3.1 Arterius Ltd Pipeline Products &Ongoing Clinical Trials Overview | 54 | 1 |
| 5.4 Biosten, LLC Company Overview | 55 | 1 |
| 5.4.1 Biosten, LLC Pipeline Products &Ongoing Clinical Trials Overview | 55 | 1 |
| 5.5 Biotronik SE &Co. KG Company Overview | 56 | 1 |
| 5.5.1 Biotronik SE &Co. KG Pipeline Products &Ongoing Clinical Trials Overview | 56 | 6 |
| 5.6 Boston Scientific Corporation Company Overview | 62 | 1 |
| 5.6.1 Boston Scientific Corporation Pipeline Products &Ongoing Clinical Trials Overview | 62 | 5 |
| 5.7 Cardionovum GmbH Company Overview | 67 | 1 |
| 5.7.1 Cardionovum GmbH Pipeline Products &Ongoing Clinical Trials Overview | 67 | 3 |
| 5.8 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview | 70 | 1 |
| 5.8.1 HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products &Ongoing Clinical Trials Overview | 70 | 1 |
| 5.9 Icon Interventional Systems, Inc. Company Overview | 71 | 1 |
| 5.9.1 Icon Interventional Systems, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 71 | 1 |
| 5.10 Japan Stent Technology Co., Ltd. Company Overview | 72 | 1 |
| 5.10.1 Japan Stent Technology Co., Ltd. Pipeline Products &Ongoing Clinical Trials Overview | 72 | 1 |
| 5.11 Kyoto Medical Planning Co., Ltd. Company Overview | 73 | 1 |
| 5.11.1 Kyoto Medical Planning Co., Ltd. Pipeline Products &Ongoing Clinical Trials Overview | 73 | 1 |
| 5.12 Lifetech Scientific (Shenzhen) Co., Ltd. Company Overview | 74 | 1 |
| 5.12.1 Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products &Ongoing Clinical Trials Overview | 74 | 1 |
| 5.13 Medlogics Device Corporation Company Overview | 75 | 1 |
| 5.13.1 Medlogics Device Corporation Pipeline Products &Ongoing Clinical Trials Overview | 75 | 1 |
| 5.14 Meril Life Sciences Pvt. Ltd. Company Overview | 76 | 1 |
| 5.14.1 Meril Life Sciences Pvt. Ltd. Pipeline Products &Ongoing Clinical Trials Overview | 76 | 3 |
| 5.15 MicroPort Scientific Corporation Company Overview | 79 | 1 |
| 5.15.1 MicroPort Scientific Corporation Pipeline Products &Ongoing Clinical Trials Overview | 79 | 2 |
| 5.16 NanoCoeur, Inc. Company Overview | 81 | 1 |
| 5.16.1 NanoCoeur, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 81 | 1 |
| 5.17 North Carolina State University Company Overview | 82 | 1 |
| 5.17.1 North Carolina State University Pipeline Products &Ongoing Clinical Trials Overview | 82 | 1 |
| 5.18 Northwestern University Company Overview | 83 | 1 |
| 5.18.1 Northwestern University Pipeline Products &Ongoing Clinical Trials Overview | 83 | 2 |
| 5.19 OrbusNeich Company Overview | 85 | 1 |
| 5.19.1 OrbusNeich Pipeline Products &Ongoing Clinical Trials Overview | 85 | 2 |
| 5.20 Pegasus Therapeutics, Llc Company Overview | 87 | 1 |
| 5.20.1 Pegasus Therapeutics, Llc Pipeline Products &Ongoing Clinical Trials Overview | 87 | 1 |
| 5.21 REVA Medical, Inc. Company Overview | 88 | 1 |
| 5.21.1 REVA Medical, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 88 | 6 |
| 5.22 S3V Vascular Technologies Company Overview | 94 | 1 |
| 5.22.1 S3V Vascular Technologies Pipeline Products &Ongoing Clinical Trials Overview | 94 | 1 |
| 5.23 Shanghai MicroPort Medical Group Co Ltd Company Overview | 95 | 1 |
| 5.23.1 Shanghai MicroPort Medical Group Co Ltd Pipeline Products &Ongoing Clinical Trials Overview | 95 | 2 |
| 5.24 Tepha, Inc. Company Overview | 97 | 1 |
| 5.24.1 Tepha, Inc. Pipeline Products &Ongoing Clinical Trials Overview | 97 | 2 |
| 5.25 VasoTech Inc. Company Overview | 99 | 1 |
| 5.25.1 VasoTech Inc. Pipeline Products &Ongoing Clinical Trials Overview | 99 | 2 |
| 5.26 Xenogenics Corporation Company Overview | 101 | 1 |
| 5.26.1 Xenogenics Corporation Pipeline Products &Ongoing Clinical Trials Overview | 101 | 4 |
| 6 Bioabsorbable Stents (BAS)- Recent Developments | 105 | 23 |
| 6.1 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer | 105 | 1 |
| 6.2 Sep 28, 2016: Nevada Heart And Vascular Center Announces Partnership With Desert Springs Hospital Offering First-Of-Its-Kind Naturally Dissolving Heart Stent For Patients With Coronary Artery Disease | 105 | 1 |
| 6.3 Aug 30, 2016: MPSC Announces 2016 Interim Results | 106 | 1 |
| 6.4 Aug 17, 2016: Fully Dissolving Stent Revolutionizes Heart Disease Treatment | 107 | 1 |
| 6.5 Aug 08, 2016: DMC Heart Hospital Offers First-Of-Its-Kind Naturally Dissolving Heart Stent To Patients With Coronary Artery Disease | 108 | 1 |
| 6.6 Aug 02, 2016: REVA Completes Submission of CE Mark Application | 108 | 1 |
| 6.7 Jul 29, 2016: Sutter Health advances cardiovascular service by offering first-of-its-kind fully dissolving heart stent in Bay Area and Sacramento | 109 | 1 |
| 6.8 Jul 29, 2016: REVA Medical: Quarter Ended 30 June 2016 | 109 | 1 |
| 6.9 Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016 | 110 | 2 |
| 6.10 Jul 27, 2016: St. John Hospital &Medical Center Implants First Dissolving Heart Stent | 112 | 1 |
| 6.11 Jul 26, 2016: New Heart Device Trialed at Mercy Wins FDA Approval | 112 | 1 |
| 6.12 Jul 25, 2016: INTEGRIS Heart Hospital Implants First-of-its-kind Naturally Dissolving Heart Stent in Patient with Coronary Artery Disease | 113 | 1 |
| 6.13 Jul 14, 2016: St. Elizabeth s Medical Center Becomes First Hospital in New England to Implant Dissolvable Heart Stent | 113 | 1 |
| 6.14 Jul 14, 2016: Health Canada Approves Abbott's Absorb Bioresorbable Stent, The First Fully Dissolving Heart Stent | 114 | 1 |
| 6.15 Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors | 115 | 1 |
| 6.16 Jul 12, 2016: Good Samaritan Hospital First on the West Coast to Offer Naturally Dissolving Heart Stent to Patients with Coronary Artery Disease | 115 | 1 |
| 6.17 Jul 08, 2016: University Hospitals Case Medical Center cardiologists first to implant Abbott Absorb Stent in Midwest | 116 | 1 |
| 6.18 Jul 05, 2016: FDA approves first absorbable stent for coronary artery disease | 117 | 1 |
| 6.19 Jul 05, 2016: Arizona patient will receive first U.S.-approved fully dissolving heart stent | 117 | 1 |
| 6.20 Jun 08, 2016: Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation | 118 | 1 |
| 6.21 Jun 06, 2016: Amaranth Medical Completes Enrollment in RENASCENT-II Study of 120-Micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold | 118 | 1 |
| 6.22 Jun 06, 2016: Amaranth Medical Completes Enrollment in RENASCENT-II Study of 120-Micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold | 119 | 1 |
| 6.23 Jun 03, 2016: LEPUCARE established in India | 119 | 1 |
| 6.24 May 18, 2016: Amaranth Medical On Track to Complete Enrollment in RENASCENT-II Study of 120-Micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold in May | 119 | 1 |
| 6.25 May 18, 2016: REVA Sponsors Symposium at EuroPCR 2016 | 120 | 1 |
| 6.26 May 17, 2016: REVA Releases Positive Clinical Results for Fantom | 120 | 1 |
| 6.27 May 11, 2016: Elixir Medical to Showcase the Next Generation Bioresorbable Novolimus Eluting Coronary Scaffold System DESolve CX at EuroPCR 2016 | 121 | 2 |
| 6.28 May 11, 2016: Elixir Medical to Showcase the Next Generation Bioresorbable Novolimus Eluting Coronary Scaffold System AMITY at EuroPCR 2016 | 123 | 1 |
| 6.29 May 10, 2016: REVA to Present at EuroPCR 2016 | 123 | 1 |
| 6.30 Apr 01, 2016: MicroPort and Yizheng Municipal Government Establishes "Shanghai-Yizheng Healthcare Cooperation Project" | 124 | 1 |
| 6.31 Mar 23, 2016: MicroPort Signs Cooperation Agreement with Beijing Weimai Medical Device | 124 | 1 |
| 6.32 Mar 15, 2016: Abbott's Absorb, the First Fully Dissolving Heart Stent, Earns Positive Review by FDA Advisory Committee | 124 | 1 |
| 6.33 Feb 23, 2016: REVA Achieves Target Patient Enrollment in FANTOM II Trial | 125 | 1 |
| 6.34 Feb 10, 2016: REVA Announces Clinical Enrollment Progress and Anticipated $11.4 Million Cash Receipt | 126 | 1 |
| 6.35 Jan 19, 2016: REVA Hires Richard Kimes as SVP of Operations | 126 | 2 |
| 7 Appendix | 128 | 4 |
| 7.1 Methodology | 128 | 2 |
| 7.2 About GlobalData | 130 | 1 |
| 7.3 Contact Us | 130 | 1 |
| 7.4 Disclaimer | 131 | 1 |